Glucocorticoid receptor in cervical cancer: an immunhistochemical analysis

Kost, Bernd; Beyer, Susanne; Schröder, Lennard; Zhou, Junyan; Mayr, Doris; Kühn, Christina; Schulze, Sandra; Hofmann, Simone; Mahner, Sven; Jeschke, Udo; Heidegger, H

doi:10.1007/s00404-018-4928-9

Cited by 13 publications

(12 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35 High glucocorticoid receptor expression has been associated with a better prognosis in cervical cancer. 53 Androgen receptor expression decreases as cervical neoplastic disease progresses, and knockdown of androgen receptor increases the invasion of cervical cancer cells in vivo. 54,55 In summary, these results indicate that MPA is efficient in preventing the development of cervical cancer from PRpositive CIN lesions.…”

Section: Discussionmentioning

confidence: 99%

Medroxyprogesterone Acetate Prevention of Cervical Cancer through Progesterone Receptor in a Human Papillomavirus Transgenic Mouse Model

Baik

Mehta

Chung

2019

The American Journal of Pathology

View full text Add to dashboard Cite

Cervical dysplastic lesions called cervical intraepithelial neoplasias (CINs) need be treated to prevent cervical cancer. Currently available surgical procedures are effective, but the development of noninvasive treatment is warranted. In human papillomavirus transgenic mice engineered to express human papillomavirus type 16 E6 and E7, short-term treatment with 17b-estradiol induces CINs that progress to cervical cancer if the treatment is continued. In the present study, this mouse model was used to determine whether medroxyprogesterone acetate (MPA), a progestin drug, is chemopreventive. Human papillomavirus transgenic mice bearing CIN lesions were treated with MPA plus 17b-estradiol. Unlike control mice treated with 17b-estradiol alone, cervical cancer was absent in the MPA-treated mice. This observation suggests that MPA prevented CIN from progressing to invasive cancer. MPA was associated with inhibited cell proliferation and the promotion of apoptosis in CIN lesions. Confirming the role of the progesterone receptor, the preventive effect of MPA was absent in human papillomavirus transgenic mice in which the expression of progesterone receptor was genetically ablated. These results suggest that MPA is efficient in treating progesterone receptorepositive CIN lesions. These findings provide the basis for a biomarker-driven clinical trial of the secondary prevention of cervical cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Medroxyprogesterone Acetate Prevention of Cervical Cancer through Progesterone Receptor in a Human Papillomavirus Transgenic Mouse Model

Baik

Mehta

Chung

2019

The American Journal of Pathology

View full text Add to dashboard Cite

show abstract

“…The antiproliferative effect of A. precatorius seed extracts may be attributed to the suppression of multiple oncogenic signaling pathways and tumor-promoting factors. In this analysis, we studied the following receptors like Glucocorticoids, Her2 and HEXB known to be associated with proliferation of cervical cancer [3][4][5]. Piperine, rutin and tannic acid exhibits a myriad of medicinal bene ts such as antioxidant, anti-in ammatory, anticancer and neuroprotective effects [21][22][23].…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, the development of novel therapeutic drugs with increased e ciency is warranted. Receptors like Glucocorticoids (GCR), Human epidermal growth factor receptor 2 (HER2) and Beta-hexosaminidase subunit beta (HEXB) are reported to be associated with progression of CaCx and have been established as promising therapeutic candidates as corroborated by in-silico analysis [3][4][5] . Out of the 1881 new chemical entities, that had been approved as drugs between 1981 and 2019, the purely synthetic compounds amount for only 24.6%, while a majority of the new drugs were derived from medicinal plants [6].…”

Section: Introductionmentioning

confidence: 99%

In Vitro Antioxidant and Antiproliferative Efficacy of Abrus precatorius Seed Extracts On Hep2c Cells and Its Inhibitory Efficacy With Receptors Of Cervical Carcinoma

Kaur¹,

Sharma²,

Waidha³

et al. 2021

Preprint

View full text Add to dashboard Cite

Abrus precatorius is a widely distributed tropical medicinal plant with several therapeutic properties, however its seed extract has not been studied against cervical cancer (CaCx) till date. Herein, we have assessed the antioxidant and antiproliferative properties of A. precatorius seed extracts (ethyl acetate and 70% ethanol) prepared from different extraction methods (Soxhlet and maceration) against human cervix carcinoma cells (Hep2C). We observed a significantly higher total flavonoid content of APE (sox) i.e.,112.7±0.127 mg Quercetin Equivalent/g of extract than others; total phenolic content of APA (mac) seed extract was higher i.e.,108.53±0.089 mg Quercetin Equivalent/g of extract and total tannin content of APA (sox) was higher i.e., 98.98± 0.011 mg tannic acid equivalents/g of extract. In addition, tannic acid, rutin and piperine were identified in extracts by HPLC. Furthermore, APA (sox) exhibited the highest radical scavenging activity with an IC50 value of 14.49±0.93µg/ml. APE (mac) showed the most significant antiproliferative activity with IC50 value of 85.90±0.93µg/mL against Hep2c cells. SOD and GST activity was observed as highest in the APA(Mac) extract whereas the catalase activity and GSH content was maximum in the APE(Mac) extract. Further, the MDA content was observed to be the least in APE(Mac) extracts. Docking results suggested maximum binding energy between tannic acid and Her2 receptor compared to doxorubicin (standard). This study provides evidence that A. precatorius seed extracts possess promising bioactive compounds with probable anticancer and antioxidant properties against CaCx which might be utilized as a possible herbal remedy aimed at restricting tumor growth.

show abstract

“…Consistency between preclinical and clinical studies on ovarian cancer supports the hypothesis that glucocorticoid signaling has a promotive effect on solid tumors. However, cervical cancer patients with higher expression of glucocorticoid receptors have longer progression-free survival and overall survival (Block et al, 2017;Kost et al, 2019). The reason for the contradiction between clinical and experimental studies on cervical cancer is unclear, and whether other signaling pathways are involved remains to be studied.…”

Section: Glucocorticoidsmentioning

confidence: 99%

Stress Hormones: Emerging Targets in Gynecological Cancers

Chen

Qiu²,

Gao

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

In the past decade, several discoveries have documented the existence of innervation in ovarian cancer and cervical cancer. Notably, various neurotransmitters released by the activation of the sympathetic nervous system can promote the proliferation and metastasis of tumor cells and regulate immune cells in the tumor microenvironment. Therefore, a better understanding of the mechanisms involving neurotransmitters in the occurrence and development of gynecological cancers will be beneficial for exploring the feasibility of using inexpensive β-blockers and dopamine agonists in the clinical treatment of gynecological cancers. Additionally, this article provides some new insights into targeting tumor innervation and neurotransmitters in the tumor microenvironment.

show abstract

Glucocorticoid receptor in cervical cancer: an immunhistochemical analysis

Cited by 13 publications

References 29 publications

Medroxyprogesterone Acetate Prevention of Cervical Cancer through Progesterone Receptor in a Human Papillomavirus Transgenic Mouse Model

Medroxyprogesterone Acetate Prevention of Cervical Cancer through Progesterone Receptor in a Human Papillomavirus Transgenic Mouse Model

In Vitro Antioxidant and Antiproliferative Efficacy of Abrus precatorius Seed Extracts On Hep2c Cells and Its Inhibitory Efficacy With Receptors Of Cervical Carcinoma

Stress Hormones: Emerging Targets in Gynecological Cancers

Contact Info

Product

Resources

About